CRCBIOSCREEN

CRCbioscreen was founded in 2021 as a spin off company from the Netherlands Cancer Institute. The company holds an exclusive license on the intellectual property of NKI's Translational Gastrointestinal Oncology group regarding a stool based screening test directed against a combination of proteins has the potential to increase sensitivity for high risk precursor lesions of colorectal cancer... CRCbioscreen is developing a novel, multi-target Faecal Immunochemical Test (mt FIT), which has improved sensitivity for high risk precursor lesions, while maintaining the same low level of false postives as the current FIT has... Our mission is to develop a superior diagnostic test for population based colorectal cancer screening than currently is available.

Also known as: CRCbioscreen BV

Primary location: Amsterdam Netherlands